a GeneOne Life Science, Inc. Seoul , Korea.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
The past decade and a half has been characterized by numerous emerging infectious diseases. With each new threat, there has been a call for rapid vaccine development. Pathogens such as the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and the Zika virus represent either new viral entities or viruses emergent in new geographic locales and characterized by novel complications. Both serve as paradigms for the global spread that can accompany new pathogens. In this paper, we review the epidemiology and pathogenesis of MERS-CoV and Zika virus with respect to vaccine development. The challenges in vaccine development and the approach to clinical trial design to test vaccine candidates for disease entities with a changing epidemiology are discussed.
过去十五年的时间里出现了许多新发传染病。每出现一种新的威胁，就会有人呼吁快速开发疫苗。中东呼吸综合征冠状病毒（MERS-CoV）和寨卡病毒等病原体要么是新的病毒实体，要么是在新的地理区域出现的新型病毒，并具有新的并发症。两者都可作为伴随新病原体出现的全球传播的范例。在本文中，我们将回顾 MERS-CoV 和寨卡病毒的流行病学和发病机制，以及它们在疫苗开发方面的情况。讨论了疫苗开发所面临的挑战，以及针对具有不断变化的流行病学的疾病实体测试疫苗候选物的临床试验设计方法。
